WUXI BIO (02269) News

Wuxi Biologics (Cayman) Stock Slips 1.4% in Hong Kong

Dow JonesMar 11 16:32

The biopharmaceutical industry has been positioned as an emerging pillar industry, with the Hang Seng Stock Connect Innovative Pharmaceutical ETF (E Fund) (159316) rising by 3.57%.

Gelonghui, March 10 | The Hong Kong-listed pharmaceutical stocks rose, with Akeso Inc. up more than 9%, 3SBio Inc. up over 6%, and Innovent Bio up over 4%, driving the Hang Seng Innovation Pharmaceutical ETF (159316) managed by E Fund to rise by 3.57%. In terms of news, in this year's government work report, the biopharmaceutical industry was explicitly listed as a 'new pillar industry' at the national level, alongside industries such as integrated circuits, aerospace, and low-altitude economy. This marks the first time that the government work report has proposed the development of the biopharmaceutical industry from the perspective of a pillar industry, sending an important policy signal to accelerate the upgrading of the sector. Dongwu Securities noted that the Two Sessions for the first time designated innovative drugs as

Gelonghui FinanceMar 10 10:42

Wuxi Biologics (Cayman) Stock Sheds 2.5% in Hong Kong

Dow JonesMar 9 16:32

Two Sessions Set New Course! Analysts Favor These Sectors as Fund Managers Map Out '2026 Investment Blueprint'

During the Two Sessions in 2026, the draft outline of the '15th Five-Year Plan' and the government work report not only provided a clear blueprint for economic development and policy direction but also signaled numerous investment opportunities.

Securities Times ChinaMar 9 08:54

Wuxi Issuing 40M Overallotment H-Shrs at HK$45.80 Each

Dow JonesMar 9 08:30

Express News | Zheng Shanjie: The output value related to the six major emerging pillar industries—integrated circuits, aerospace, biomedicine, and others—is expected to exceed 10 trillion yuan by 2030.

BreakingsMar 6 16:46

Hong Kong-listed innovative pharmaceutical companies are leveraging policy support. Institutions: The biopharmaceutical sector is transitioning from an 'R&D investment phase' to a 'value harvest phase.'

① Why has the biopharmaceutical sector recently attracted significant market attention? ② How do institutions view recent policies?

cls.cnMar 6 14:05

Surging BD transactions and policy catalysts! The Hang Seng Medicine ETF (159892) surged by 3.67%, while the HK Connect Healthcare ETF (520510) rose by 2.89%, with its real-time turnover rate ranking first among similar products.

Gelonghui, March 6th | Today, the innovative drug sector rebounded strongly. The constituent stock 3SBio Inc. surged by 10%, driving the Hang Seng Medicine ETF (159892) to rise by 3.67%. The Stock Connect Healthcare ETF (520510) increased by 2.89%, with a turnover rate of 54.58%, ranking first among similar products. In terms of news: ① The 2026 Government Work Report identifies new quality productive forces as a core focus, listing biomedicine alongside integrated circuits, aerospace, and low-altitude economy for the first time, clearly defining it as a national 'emerging pillar industry.' It is expected that innovative drugs will receive more concentrated policy support, funding, and resource allocation. ② Business development (BD) transactions continue.

Gelonghui FinanceMar 6 13:01

The innovative drug sector has rebounded strongly, driven by both policy support and industrial momentum, with the low-cost Hang Seng Stock Connect Innovative Drug ETF (E Fund) (159316) rising over 3%.

Gelonghui March 6th | The Hang Seng Stock Connect Innovative Pharmaceutical ETF (159316), managed by E Fund, surged over 3.9% in the morning session, becoming the top-performing sector-specific ETF during that period. From a news perspective, the industry is experiencing multiple catalysts. Policy catalyst: The government work report has mentioned innovative pharmaceuticals for three consecutive years, and biomedicine has been elevated to an 'emerging pillar industry.' In the 2026 government work report, biomedicine was, for the first time, listed alongside integrated circuits, aerospace, and low-altitude economy, clearly defined as a national 'emerging pillar industry.' With the elevation of strategic positioning, innovative pharmaceuticals are expected to receive more concentrated policy support, funding, and resource allocation. This is further reinforced by the report's proposal to 'launch commercial'

Gelonghui FinanceMar 6 10:55

The concept of innovative pharmaceuticals in Hong Kong stocks has gained momentum, with biomedicine emerging as a 'new pillar industry' for the first time. Both business development (BD) and financial performance are expected to serve as dual drivers.

The innovative drug sector strengthened during early trading. As of press time, 3SBio Inc. surged nearly 9%, Hutchison China MediTech rose over 8%, Innovent Bio climbed nearly 6%, Hengrui Pharma increased more than 5%, and Connaught Medical-B gained 5%.

Zhitong FinanceMar 6 10:22

Wuxi Biologics (Cayman) Stock Slides 3.7% in Hong Kong

Dow JonesMar 2 16:32

WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

PR NewswireMar 2 11:21

Another deal signed! The total BD value of China's innovative drugs has exceeded $500 billion in just two months.

① Wuxi XDC announced today that it has reached a licensing agreement with an AI-driven biotechnology company to accelerate the development of next-generation ADC drugs. ② The total potential value of this collaboration is expected to exceed 800 million US dollars, but notably, the upfront payment amount was not disclosed in this transaction. ③ Data shows that since the beginning of this year, the total value of China's innovative drug BD transactions has surpassed 50 billion US dollars.

cls.cnFeb 27 22:57

Data Insights | What did northbound capital buy in February? Significant fund inflows observed, with over HKD 21.6 billion added to Tencent holdings.

Since February, southbound capital has made a strong comeback with the posture of 'seizing pricing power,' initiating a 'shopping spree' mode. Notably, from February 4th to 6th and on the 13th, northbound capital recorded daily net purchases consistently above HKD 10 billion, with some trading days even surging to the HKD 20 billion level, reflecting an exceptionally robust inflow trend.

Futu NewsFeb 27 19:22

Market Snapshot | Three major indices closed higher, with the Hang Seng Index up nearly 1%. Electric power and innovative pharmaceutical concept stocks advanced, Datang Power surged over 6%, and Wuxi Bio climbed more than 5%. Changfei Fiber Optic Cable so

Technology and internet stocks generally rose, with SenseTime-W up 4.92% and NetEase-S up 2.40%. Real estate developer stocks advanced, as Country Garden surged 7.58% and Sun Hung Kai Properties climbed 7.12%. Biotechnology stocks also performed well, with Wuxi XDC gaining 8.23% and Wuxi Bio rising 5.07%.

Futu NewsFeb 27 16:25

Express News | Hong Kong Stocks Close: Hang Seng Index Rises 0.95% Amid Volatility, Led by Steel and Coal Sectors

BreakingsFeb 27 16:14

Profit alerts from multiple companies have driven a recovery in Hong Kong's stock market for innovative drug makers, while pharmaceutical enterprises' outbound business development (BD) remains robust at the start of the year.

Following the recent release of strong earnings reports by several biopharmaceutical stocks, the innovative drug concept in Hong Kong's stock market also became active again today.

cls.cnFeb 27 15:43

Stock Movement in Hong Kong | CXO Concept Stocks Lead Gains: Wuxi XDC (02268) Surges Over 8%, Wuxi Bio (02269) Rises More Than 4%

CXO concept stocks led the gains, with Wuxi XDC (02268) rising 7.97% to HKD 63; Wuxi Bio (02269) increasing 4.7% to HKD 40.08; Wuxi Apptec (02359) climbing 2.28% to HKD 19.7; and ChemPartner (03759) also rising 2.28% to HKD 19.7.

Zhitong FinanceFeb 27 14:14

CLSA, a major brokerage, has a positive outlook on the earnings visibility of CDMO companies and lists Wuxi Apptec (02359.HK), Wuxi Bio (02269.HK), and Canmed Pharmaceutical (03759.HK) as its top picks.

In a research report, CLSA noted that as AI technology continues to advance, investors' focus has recently shifted from AI-enabled industries to AI replacing intermediaries. For contract research organizations (CROs) and contract manufacturing organizations (CDMOs), it is expected that AI will have a more pronounced positive impact on comprehensive contract research, development, and manufacturing organizations (CRDMOs). In contrast, the accelerated adoption of AI by pharmaceutical companies internally may have mixed implications for specialized CROs. Therefore, CLSA currently favors CDMOs, expecting them to outperform CROs in terms of profit visibility due to better capacity-locking capabilities and longer-term projects.

AASTOCKSFeb 27 11:50

CLSA commented that the decline of Wuxi Bio (02269.HK) and Wuxi XDC (02268.HK) on Thursday was not driven by fundamental factors.

In a report, CLSA noted that Wuxi Bio (02269.HK) and Wuxi XDC (02268.HK) fell approximately 7% and 8%, respectively, on Thursday (the 26th), while the overall decline for Hong Kong-listed CRO/CDMO companies ranged from about 2% to 9%. The brokerage firm believes that this decline was not driven by fundamentals but was more likely led by position adjustments and capital flows. The report states that the current pullback represents a technical/short-term fluctuation rather than a deterioration in demand or execution capabilities. During a market window period lacking catalysts, industry leaders may still experience overselling, creating a more attractive entry point for investors with a 3- to 12-month investment horizon.

AASTOCKSFeb 27 11:13